# EDGAR Filing Document

**Accession Number:** 0001671502
**File Stem:** 0001104659-25-117689
**Filing Date:** 2025-12
**Character Count:** 3033
**Document Hash:** 4d5de974fe55988242c7e45bd436a7c8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-117689.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001104659-25-117689

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quoin Pharmaceuticals, Ltd.
- **CENTRAL INDEX KEY:** 0001671502
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425
- **BUSINESS PHONE:** 97299741444

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biotechnology Ltd.
- **DATE OF NAME CHANGE:** 20160721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biomed Ltd.
- **DATE OF NAME CHANGE:** 20160406

![](tm2530425d2_correspimg001.jpg)

December 2, 2025

 ****

***<u>VIA EDGAR</u>***

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Dan Crawford

---

| | |
|:---|:---|
| **Re:** | **Quoin Pharmaceuticals, Ltd.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed November 7, 2025**<br> **File No: 333-291385** |

---

Dear Mr. Crawford:

Quoin Pharmaceuticals, Ltd. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-291385) (the **"Registration Statement**") be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Thursday, December 4, 2025**, at **5:00 p.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify Ms. Murawsky when this request for acceleration has been granted.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **QUOIN PHARMACEUTICALS, LTD.** | **QUOIN PHARMACEUTICALS, LTD.** | **QUOIN PHARMACEUTICALS, LTD.** |
| By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ Michael Myers | &nbsp;&nbsp;&nbsp;&nbsp;/s/ Michael Myers |
|  | Name: | Dr. Michael Myers |
|  | Title: | Chief Executive Officer |

---

cc: Melissa Palat Murawsky, Esq., Blank Rome LLP